Susanna Greer: A New Playbook for Head and Neck Cancer Treatment
Susanna Greer, Chief Scientific Officer at the V Foundation, shared a post on LinkedIn:
“A New Playbook for Head and Neck Cancer Treatment.
Head and neck cancers affect over 65,000 Americans each year, with survival rates stubbornly low for patients with HPV-unrelated cancers.
Research in the lab of the V Foundation grantee Dr. Sana Karam, Vice Chair of Translational Research, Marsico Endowed Chair in Head and Neck Cancer and Professor University of Colorado School of Medicine, targets a crucial but tricky signaling pair in these cancers: EphB4 and ephrinB2, which act like rival coaches giving opposing game plans.
These mixed signals can either help contain the tumor or, worse, encourage it to spread.
To tackle this, the Karam lab used a precision tool called a fusion protein – a custom-built molecule that acts like a smart lockpick. It targets only the problematic signals, blocking cancer-promoting activity while sparing healthy cells. The result?
By blocking ephrinB2 in blood vessels, they strengthened the body’s natural barriers against cancer spread and supercharged the immune system. In preclinical models, Dr. Karam’s team found this led to both reduced local tumor growth and fewer lung metastases.
For patients, this could mean a shift toward treatments that are more precise, with fewer side effects, and a stronger immune response – especially for those with aggressive, hard-to-treat cancers. Next steps include exploring these fusion proteins in clinical trials, aiming to bring new hope to patients facing limited options. I love this paper, fantastic work Dr. Karam and team!
Find the Karam lab and read this incredible paper here.”
More posts featuring Susanna Greer.
Susanna F. Greer is the Chief Scientific Officer at the V Foundation. Before this role, Dr. Greer was a Senior Scientific Director at the American Cancer Society, where she led the Biochemistry and Immunology of Cancer Research Program.
Greer’s work focuses on identifying crucial signaling pathways in the immune response to cancer and has led to significant discoveries in molecular immunology and new epigenetic targets.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023